Starting 1 January, Luxembourg will significantly reduce the prescription of cannabis flowers as part of its cannabis program.
The government justifies its decision to limit the use of medical cannabis by citing a lack of scientific evidence supporting its effectiveness, while also aiming to curb potential abuse. As a result, patients will only be able to access THC-limited cannabis oil extracts. However, the patient advocacy group Cannamedica warns that this change could have serious repercussions for those who rely on the programme.
Line Olinger from Cannamedica explains that cannabis oils may not offer the same therapeutic benefits as cannabis flowers, as the THC levels differ. "The effectiveness lies in the combination of substances. Patients should be able to determine their own optimal dosage, as this is highly individual. A high CBD and low THC content might work for some, but not for others. Individualisation is crucial for effective treatment."
Olinger highlights that cannabis is often used to alleviate symptoms of chronic illnesses, and reducing the THC content could reduce its efficacy for many patients, ultimately leading to a loss of quality of life. She also points out that transitioning to new products can be disruptive for patients who are accustomed to their current treatment.
"This new regulation is not the solution," Olinger states. "It’s unfair to those who genuinely depend on the program as it is. I’m not sure what the Ministry of Health has in mind." She also emphasises that the new regulation is discouraging for patients who are being penalised for the misuse of cannabis by others and hopes that a better solution can be found. Currently, the programme ensures patients have access to safe and regulated cannabis, unlike the risks associated with homegrown plants.
